Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of … – GlobeNewswire (press release)
|
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of …
GlobeNewswire (press release) NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031, developed by … |
